Current filters:


Popular Filters

8030 to 8054 of 8756 results

Prior CHMP positive benefit-risk for pioglitazone confirmed; EMA starts NSAIDS review


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has clarified its…

ActosDiabetesEuropeNeurologicalPharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Actelion granted motion for new trial in Asahi damages dispute


Europe’s largest biotech company, Actelion (SIX: ATLN), announced this morning that, the Superior…

ActelionAsahi KaseiBiotechnologyfasudilFinancialLegal

Par Pharma challenges FDA authority on off-label promotion


In what may be a game-changer for drug companies, a court in the US District of Columbia has been asked…

Markets & MarketingMegace ESPar PharmaceuticalsPharmaceuticalRegulation

On the issue of delaying generics, South Africa’s pharma market not comparable with the USA, expert says


A recent report by the US competition authority, the Federal Trade Commission, on the short and long-term…

GenericsPatentsRest of the World

Canada’s Rx&D urges government to conclude CETA with EU on improved IP


Commenting on the imminent conclusion of the ninth round of trade talks between Canada and the European…

North AmericaPatentsPharmaceuticalPolitics

Generics to constrain growth of Parkinson’s disease drug market through 2020


Over the next decade, the Parkinson’s disease (PD) drug market in the leading countries (USA, France,…

GenericsGlobalMarkets & MarketingNeurologicalPharmaceutical

Eli Lilly 3rd-qtr 2011 sales grow 9% but costs hit profits


US drug major Eli Lilly (NYSE: LLY) posted financial results for the third quarter of 2011 showing that,…

Eli LillyFinancialPharmaceutical

Syntaxin and Ipsen in up to $99 million collaboration on novel botulinum-toxin therapeutics


French drugmaker Ipsen (Euronext: IPN) has entered into a global strategic collaboration with privately-held…


Executive appointments at Bristol-Myers Squibb and Amgen


US drug major Bristol-Myers Squibb (NYSE: BMY) has announced a series of related changes within its senior…

AmgenBiotechnologyBristol-Myers SquibbManagementPharmaceutical

Benefits of Boehringer’s Pradaxa come at high cost, study finds


Treating patients with the new blood thinning medication dabigatran (German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaPricing

Prasco selected as Eli Lilly authorized generics partner for Zyprexa


Privately-held US drugmaker Prasco Laboratories says it has signed a marketing and distribution agreement…

Eli LillyGenericsMarkets & MarketingNeurologicalNorth AmericaPrasco LaboratoriesZyprexa

Over 230K US pharma jobs will be lost under proposed mandatory Part D drug rebates, says think tank


US President Barack Obama and some members of Congress have proposed requiring that prescription drug…

HealthcareNorth AmericaPharmaceuticalPoliticsPricingResearch

Sun Pharma offers to acquire remainder of Taro shares


Indian drugmaker Sun Pharmaceuticals (SUN: BO) has proposed to acquire the remaining shares of Israel-based…

GenericsMergers & AcquisitionsPharmaceuticalSun Pharmaceutical IndustriesTaro Pharmaceuticals

Atrial fibrillation drug market to increase nearly eight-fold to over $10 billion in 2020


The atrial fibrillation drug market will increase nearly eight-fold over the next decade, growing from…

Cardio-vascularEliquisGlobalMarkets & MarketingPharmaceuticalPradaxaXarelto

Litigation hits Abbott Lab’s 3rd-qtr, but shares leap as firm says it will split in two


US health care major Abbott Laboratories (NYSE: ABT) saw its shares leap 10% in morning trading yesterday,…

Abbott LaboratoriesFinancialPharmaceutical

GlaxoSmithKline warned by US FDA over cGMP violations at UK plant; positive malaria vaccine news


UK pharma giant GlaxoSmithKline ILSE: GSK) has received a warning letter from the US Food and Drug Administration…

Antibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalRegulationResearchVaccines

Servier links with Miragen for cardiovascular drugs; takes up Ampakine option


Laboratoires Servier , France’s largest independent drugmaker has entered into a research, development…

Cardio-vascularCortex PharmaceuticalsLicensingmiRagen TherapeuticsNeurologicalPharmaceuticalServier

Vertex files for US priority review and approval of Kalydeco for cystic fibrosis


USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) says it has filed a New Drug Application with the Food…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Actelion posts 85.6 Swiss franc loss for first nine months of 2011


Switzerland-based Actelion (ATLN: VX) recorded an operating loss of 85.6 million Swiss francs ($95.5…


8030 to 8054 of 8756 results

Back to top